Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab in advanced biliary tract tumors
ChiCTR2100049971Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in biliary cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100049971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049971.